GeNeuro announces the publication in Multiple Sclerosis of results from CHANGE-MS and ANGEL-MS studies

Geneva, Switzerland, July 15, 2021 – 08:00am CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical developing new treatments for neurodegenerative diseases, such as multiple sclerosis (MS), today announced publication in Multiple Sclerosis of the safety and efficacy results from its temelimab CHANGE-MS and ANGEL-MS clinical studies. https://geneuro.ch/data/news/GeNeuro-PR-MSJournal-publication-EN.pdf